Last reviewed · How we verify
Superficial skin swabs
At a glance
| Generic name | Superficial skin swabs |
|---|---|
| Sponsor | Assistance Publique - Hôpitaux de Paris |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Study of Skin and Gut Microbiome in a Skin Condition Involving Skin Barrier Impairment and Allergic Symptoms: Netherton Syndrome
- Human Internal BIOASTER's Samples Collection
- Identification of Cutaneous and Blood Biomarkers Predictive of Response to Systemic Treatments During Chronic Inflammatory Skin Diseases
- MNK Therapy in Releasing the Superficial Fascia for Patients With AAS: an Assessor-blinded, Randomised Controlled Trial (NA)
- Efficacy and Safety of Dioxidin Versus Miramistin in Superficial Pyoderma (PHASE3)
- Skin Barrier Assessment in Pregnancy and at Birth
- Changes in Bacterial Flora Among Patients With Pelvic Bedsores: a Prospective Pilot Study
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Superficial skin swabs CI brief — competitive landscape report
- Superficial skin swabs updates RSS · CI watch RSS
- Assistance Publique - Hôpitaux de Paris portfolio CI